CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry (MASS-FIX) (CPT 0077U)

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyM-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry (MASS-FIX) (CPT 0077U)

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionWhen submitting CPT 0077U, file one of the listed covered ICD-10-CM diagnosis codes to support medical necessity for covered indications; verify member-specific benefits and contract exclusions prior to ordering/testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes.

1Primary CPT code covered

6Required ICD-10 diagnoses listed

1Not-covered indication (screening)

Coverage Summary

Policy governs clinical coverage of serum/urine mass spectrometry (MALDI-TOF MS, MASS-FIX) for detection, isotyping, confirmation, and monitoring of monoclonal gammopathies for Medicare Advantage and commercial products, and specifies covered CPT and required ICD-10 diagnoses. The policy specifically covers CPT 0077U when filed with the listed ICD-10 diagnoses. Coverage stance: mixed — MS is covered for certain diagnostic and monitoring indications but excluded for screening.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity / Coverage Criteria

Medically Necessary Uses (Medicare Advantage and Commercial Products)

Covered when the following covered indications are present and filed with a covered ICD-10 diagnosis:

ANY of the following

To confirm a serum protein electrophoresis (SPEP) or serum free light-chain (sFLC) abnormality
To discriminate between therapeutic monoclonal antibodies and endogenous M-proteins
For monitoring: treatment response assessment per guidelines

General Applicability / Benefit Variation

Benefit applicability depends on subscriber contract language

Benefits may vary between groups and contracts; refer to member Benefit Booklet, Evidence of Coverage, or subscriber agreement for laboratory testing benefits/coverage

Some self-funded groups may have contract exclusions per the Biomarker Testing Mandate; check contract-specific coverage and related Genetic/PLA policies

Not Covered Indications

Not Covered

MS is not covered for screening for monoclonal gammopathies

Mass spectrometry (MALDI-TOF MS / MASS-FIX) for screening for MGs

Guideline support notes that the CAP/AACC/ASCP collaborative guideline and the IMWG acknowledge mass spectrometry as an alternative to serum immunofixation electrophoresis (sIFE) to confirm a SPEP or sFLC abnormality, but the guidelines specifically recommend against MS for screening.

Provider Actions & Billing Guidance

Documentation Required

File Covered Indication with Claim

When submitting CPT 0077U, file one of the listed covered ICD-10-CM diagnosis codes to support medical necessity for covered indications.

Affected code: 0077U
File one of the listed ICD-10-CM codes: C88.0; C90.00; C90.01; C90.02; D47.2; E85.81

Documentation Required

Check Contract-Specific Benefits

Verify member-specific benefits and any contract exclusions prior to ordering or testing.

Benefits may vary by group/contract — check the member Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.
Some self-funded groups may have contract exclusions per the Biomarker Testing Mandate; confirm whether the member's plan excludes expanded biomarker/genetic/PLA coverage.

Verify member-specific laboratory testing benefits and any contract exclusions by checking the member’s Benefit Booklet, Evidence of Coverage, or subscriber agreement before ordering or submitting CPT 0077U.

Background & Definitions

Monoclonal gammopathies encompass a spectrum from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma and AL amyloidosis. Traditional detection uses serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (sIFE), and serum free light-chain (sFLC) testing. MALDI-TOF mass spectrometry (MASS-FIX) combines nanobody enrichment of immunoglobulins with MALDI-TOF MS and can detect, isotype, and in some studies quantify M-proteins with higher analytical sensitivity in certain settings and help distinguish therapeutic monoclonal antibodies from endogenous M-proteins.

Term	Definition
MASS-FIX	Nanobody enrichment of immunoglobulins followed by MALDI-TOF mass spectrometry to detect and isotype M-proteins.
M-protein	Monoclonal immunoglobulin protein produced by a single clone of plasma cells; may be intact immunoglobulin or light chain only.

CPT 0077U (Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine; including isotype) is referenced as covered when filed with one of the listed ICD-10-CM diagnosis codes (C88.0, C90.00, C90.01, C90.02, D47.2, E85.81).

Type	Number	Name	Effective Date
LCD	L39189	Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)
NCD	458921	Local Coverage Article: Coding: Mass Spectrometry Testing in Monoclonal Gammopathy (MG)